Dato-DXd plus rilvegostomig · TROPION-Lung10
The sponsor confirms recruiting first-line PD-L1-high nonsquamous NSCLC. Freeze the biomarker subgroup and combination/comparator arms; Datroway approval in another setting is unrelated. datopotamab deruxtecan — phase 3 study in Non-Small Cell Lung Cancer. NCT06357533 lists Progression-Free Survival (PFS) in TROP2 biomarker positive participants. as a primary outcome (Approximately 4 years). Registry status: recruiting.
What matters
Track what the company has actually announced, the study or asset involved, and the evidence needed to confirm the milestone.
- Specify the exact future analysis/cohort and verify that it remains unpublished before creating any tradeable question.
- Registry design and recruitment status are not evidence of efficacy or regulatory approval.
- Primary completion is not a guaranteed topline publication or regulatory decision date.
- Registry primary completion: 2029-12-28 (estimated); verify independently before using it as a catalyst date.
- An active study record does not establish that its primary outcome is still unannounced. Review sponsor disclosures before promotion to a future catalyst.
- The registry lists 2 primary outcome measures. A market must explicitly specify which endpoint or conjunction resolves YES; this card highlights one measure only.
Primary evidence
Recruiting Phase 3 — result date unconfirmed
Potential outcome market
Will datopotamab deruxtecan meet the prespecified primary endpoint in NCT06357533 by a listing deadline still to be specified?
This event is research, not a listed market. A market needs a precise question, resolution rules and liquidity before trading opens.